Welcome to our dedicated page for Orasure Tech SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OraSure Technologies Inc. filings document the regulatory record of a Nasdaq-listed diagnostics and sample management company. Its Form 8-K reports cover quarterly and annual operating results, Regulation FD presentations, business developments, board changes, and material agreements tied to shareholder and governance matters.
OraSure's proxy materials disclose director elections, executive compensation, board committee structure, shareholder voting matters and governance proposals, including matters related to board classification. The filings also identify the company's common stock listing, capital structure, risk and governance disclosures, and formal records for cooperation agreements, director appointments, resignations and investor communications.
OraSure Technologies, Inc. reported that the U.S. Food and Drug Administration granted clearance for its Colli-Pee™•Dx Urine Collection Kit, developed by subsidiary DNA Genotek Inc., for use with several Roche Molecular Systems tests for common sexually transmitted infections.
The kit is cleared for use with Roche tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium on Roche’s cobas® 5800, 6800, and 8800 molecular diagnostic systems. The FDA-cleared kit supports at-home self-collection of first-void urine, enabling more convenient sample collection for both male and female patients.
McMahon Robert W. reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director Robert W. McMahon received an equity grant as board compensation. He was awarded 46,106 shares of common stock as restricted stock, at no cash cost, increasing his direct holdings to 123,137 shares.
The restricted shares were granted under the OraSure Technologies, Inc. Stock Award Plan and will vest in full on the earlier of June 3, 2027 or immediately before the company’s 2027 Annual Meeting of Stockholders. Vesting will stop, and unvested shares will not vest, if he voluntarily leaves the Board of Directors before that time.
Gagliano Nancy J reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director Nancy J. Gagliano received a grant of 46,106 shares of common stock as a stock award. The grant consists of restricted shares under the OraSure Technologies, Inc. Stock Award Plan, provided as compensation rather than an open-market purchase.
The restricted shares will vest in full on the earlier of June 3, 2027, or immediately before the start of the company’s 2027 annual stockholders meeting, as long as she continues serving on the board. Vesting will stop immediately if she voluntarily leaves the board, so the award is tied to ongoing service. Following this grant, she holds 185,055 shares directly.
Marmora Lelio reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director Lelio Marmora received a grant of 46,106 shares of Common Stock as a stock award, not through an open-market purchase. The shares were granted at no cash cost as part of the OraSure Technologies, Inc. Stock Award Plan.
The restricted shares will vest in full on the earlier of June 3, 2027, or immediately before the start of the company’s 2027 Annual Meeting of Stockholders, provided Marmora continues to serve on the board. Vesting stops immediately if he voluntarily leaves the board. After this grant, he directly holds 148,460 shares.
Kenny John P. reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director John P. Kenny received a grant of 46,106 shares of Common Stock as a stock award. The grant was made at a price of $0.00 per share, increasing his direct holdings to 209,714 shares after the transaction.
According to the award terms, these restricted shares will vest in full on the earlier of June 3, 2027 or immediately before the start of the company’s 2027 Annual Meeting of Stockholders. Vesting will stop immediately if he voluntarily leaves the Board before that time.
Bertrand John D. reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director John D. Bertrand received a grant of 46,106 shares of Common Stock as an equity award. The shares are restricted and were granted at no cash cost to him.
The award vests in full on the earlier of June 3, 2027 or immediately before the company’s 2027 Annual Meeting of Stockholders, provided he continues serving on the Board. Vesting stops if he voluntarily leaves the Board, meaning unvested shares would not be earned. After this grant, he directly holds 79,767 OraSure shares.
Boyd Steven Kyle reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director Steven Kyle Boyd received a grant of 46,106 shares of common stock as a restricted stock award. The shares were granted at no cash cost to him and are part of the OraSure Technologies, Inc. Stock Award Plan.
These restricted shares will vest in full on the earlier of June 3, 2027, or immediately before the start of the company’s 2027 Annual Meeting of Stockholders, as long as he continues to serve on the Board. If he voluntarily leaves the Board before that time, vesting stops immediately. After this grant, Boyd directly holds 159,568 OraSure shares.
OraSure Technologies, Inc. held its 2026 annual stockholder meeting, where stockholders approved an amendment and restatement of the 2000 Stock Award Plan to add authorization for 5,000,000 additional shares of common stock for awards. Stockholders also approved an amendment to the Certificate of Incorporation to declassify the board of directors over three years beginning with the fiscal 2027 annual meeting, so directors standing for election then and thereafter will serve one-year terms.
All three Class II director nominees were elected, Grant Thornton LLP was ratified as independent auditor for 2026, and the advisory vote on executive compensation passed. As of the April 10, 2026 record date, there were 71,965,612 shares of common stock outstanding.
OraSure Technologies Inc. director Steven Kyle Boyd reported a series of open-market purchases of the company’s Common Stock. Over three days, he bought a total of 75,000 shares at prices between $2.98 and $3.02 per share. Following these transactions, he directly owned 113,462 shares.
Bertrand John D. reported acquisition or exercise transactions in this Form 4 filing.
OraSure Technologies director John D. Bertrand received a grant of 33,661 shares of common stock as an equity award. The shares were granted at no cash cost to him and are structured as restricted stock. They cliff vest on May 12, 2028, meaning the entire award vests at once on that date if he continues serving on the Board. Vesting stops immediately if he voluntarily leaves the Board before that date.